Patients' health care resources utilization and costs estimation across cardiovascular risk categories: insights from the LATINO study.
Atherosclerosis
Cardiovascular diseases
Electronic health records
Health care costs
Health resources
Risk factors
Journal
Health economics review
ISSN: 2191-1991
Titre abrégé: Health Econ Rev
Pays: Germany
ID NLM: 101583209
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
25
03
2024
accepted:
21
08
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Atherosclerotic Cardiovascular Disease (ASCVD) is a global public health concern. This study aimed to estimate the healthcare resource utilization (HRU) and costs stratified by cardiovascular disease (CVD) risk categories using real-world evidence, in a regional population in Portugal. This is a retrospective observational study, using data from Electronic Health Records between 2017 and 2021. Patients aged ≥ 40 years, and with at least one general practitioner (GP) appointment in the 3 years before 31st of December 2019, were included. CVD risk categories were determined based on 2021 ESC prevention guidelines. HRU encompassed hospital data (hospitalizations, outpatient and emergency room visits) and GP appointments. Total direct costs per patient were calculated based on the reference cost of the Portuguese legislation for payment methodology on Diagnosis-Related Groups (DRGs). Analysis of 3 122 695 episodes, revealed consistent HRU and costs across the five years. Very high-risk patients, showed higher HRU, particularly in hospital admissions. Costs tended to rise with higher CVD risk level. Very high-risk patients with ASCVD had higher costs for hospital admissions, while low-to-moderate risk patients had higher costs for GP visits. Despite a smaller proportion, very high-risk patients with prior ASCVD represent the highest costs per patient across healthcare settings (from 115€ in emergency visits to 2 673€ in hospitalizations), followed by very high-risk patients without prior ASCVD (ASCVD-risk equivalents). This study revealed a substantial HRU and costs by patients with very high CVD risk, particularly those with prior ASCVD. Moreover, ASCVD-risk equivalents emerge as notable consumers, emphasizing the importance of risk assessment and preventive measures in cost-effective management of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Atherosclerotic Cardiovascular Disease (ASCVD) is a global public health concern. This study aimed to estimate the healthcare resource utilization (HRU) and costs stratified by cardiovascular disease (CVD) risk categories using real-world evidence, in a regional population in Portugal.
METHODS
METHODS
This is a retrospective observational study, using data from Electronic Health Records between 2017 and 2021. Patients aged ≥ 40 years, and with at least one general practitioner (GP) appointment in the 3 years before 31st of December 2019, were included. CVD risk categories were determined based on 2021 ESC prevention guidelines. HRU encompassed hospital data (hospitalizations, outpatient and emergency room visits) and GP appointments. Total direct costs per patient were calculated based on the reference cost of the Portuguese legislation for payment methodology on Diagnosis-Related Groups (DRGs).
RESULTS
RESULTS
Analysis of 3 122 695 episodes, revealed consistent HRU and costs across the five years. Very high-risk patients, showed higher HRU, particularly in hospital admissions. Costs tended to rise with higher CVD risk level. Very high-risk patients with ASCVD had higher costs for hospital admissions, while low-to-moderate risk patients had higher costs for GP visits. Despite a smaller proportion, very high-risk patients with prior ASCVD represent the highest costs per patient across healthcare settings (from 115€ in emergency visits to 2 673€ in hospitalizations), followed by very high-risk patients without prior ASCVD (ASCVD-risk equivalents).
CONCLUSION
CONCLUSIONS
This study revealed a substantial HRU and costs by patients with very high CVD risk, particularly those with prior ASCVD. Moreover, ASCVD-risk equivalents emerge as notable consumers, emphasizing the importance of risk assessment and preventive measures in cost-effective management of these patients.
Identifiants
pubmed: 39264520
doi: 10.1186/s13561-024-00550-2
pii: 10.1186/s13561-024-00550-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73Informations de copyright
© 2024. The Author(s).
Références
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular diseases and Risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
doi: 10.1016/j.jacc.2020.11.010
pubmed: 33309175
pmcid: 7755038
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23(6). https://doi.org/10.3390/ijms23063346
Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of Atherothrombotic Disease. Circ Res. 2016;118(4):535–46.
doi: 10.1161/CIRCRESAHA.115.307611
pubmed: 26892956
Global Health Estimates. Life expectancy and leading causes of death and disability. [cited 2023 Apr 7]. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
doi: 10.1016/j.jacc.2017.04.052
pubmed: 28527533
pmcid: 5491406
Plano Nacional. de Saúde 2021–2030. PNS 2030. 2019.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.
doi: 10.1093/eurheartj/ehab484
pubmed: 34458905
Araújo F, Seabra D, Afonso-Silva M, Grangeia D, Taveira-Gomes T, Gavina C. Cardiovascular outcomes according to risk category: results of a retrospective database study. Atherosclerosis. 2022;355:96–7.
doi: 10.1016/j.atherosclerosis.2022.06.518
Gavina C, Carvalho DS, Pardal M, Afonso-Silva M, Grangeia D, Dinis-Oliveira RJ et al. Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data. J Clin Med Res. 2022;11(22). https://doi.org/10.3390/jcm11226825
Gavina C, Seabra Carvalho D, Afonso-Silva M, Brandão Abreu D, Canelas-Pais M, Taveira-Gomes T et al. Long-term cardiovascular outcomes in a population-based multicentric cohort of northern Portugal: Validation of the ESC/EAS prognostic risk classification. J Clin Lipidol. 2024; https://www.sciencedirect.com/science/article/pii/S1933287424000497
Govender RD, Al-Shamsi S, Soteriades ES, Regmi D. Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study. BMC Cardiovasc Disord. 2019;19(1):253.
doi: 10.1186/s12872-019-1231-z
pubmed: 31711429
pmcid: 6849175
Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. Event rates and risk factors for recurrent Cardiovascular events and mortality in a contemporary Post Acute Coronary Syndrome Population representing 239 234 patients during 2005 to 2018 in the United States. J Am Heart Assoc. 2022;11(9):e022198.
doi: 10.1161/JAHA.121.022198
pubmed: 35475346
pmcid: 9238606
Lindh M, Banefelt J, Fox KM, Hallberg S, Tai M-H, Eriksson M, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):225–32.
doi: 10.1093/ehjqcco/qcy058
pubmed: 30649251
pmcid: 6613595
Gliedt JA, Spector AL, Schneider MJ, Williams J, Young S. A Description of Theoretical Models for Health Service Utilization: A Scoping Review of the Literature. Inquiry. 2023;60:469580231176855.
Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of Cardiovascular Disease in the United States. Circulation. 2011;123(8):933–44.
doi: 10.1161/CIR.0b013e31820a55f5
pubmed: 21262990
Timmis A, Vardas P, Townsend N, Torbica A, Katus H, Smedt D, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716–99.
doi: 10.1093/eurheartj/ehab892
pubmed: 35016208
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics-2022 update: a Report from the American Heart Association. Circulation. 2022;145(8):e153–639.
doi: 10.1161/CIR.0000000000001052
pubmed: 35078371
CVD statistics. [cited 2023 May 15]. https://www.ehnheart.org/cvd-statistics.html
Costa J, Alarcão J, Amaral-Silva A, Araújo F, Ascenção R, Caldeira D, et al. Atherosclerosis: the cost of illness in Portugal. Rev Port Cardiol. 2021;40(6):409–19.
doi: 10.1016/j.repc.2020.08.007
pubmed: 34274081
Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, et al. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries. Diabetes Obes Metab. 2022;24(7):1277–87.
doi: 10.1111/dom.14698
pubmed: 35322567
pmcid: 9321691
Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.
doi: 10.1016/j.lanepe.2022.100438
pubmed: 36090671
pmcid: 9459126
Allen NB, Zhao L, Liu L, Daviglus M, Liu K, Fries J, et al. Favorable Cardiovascular Health, Compression of Morbidity, and Healthcare costs: forty-year Follow-Up of the CHA Study (Chicago Heart Association Detection Project in Industry). Circulation. 2017;135(18):1693–701.
doi: 10.1161/CIRCULATIONAHA.116.026252
pubmed: 28461414
pmcid: 5476215
Shaw LJ, Goyal A, Mehta C, Xie J, Phillips L, Kelkar A, et al. 10-Year resource utilization and costs for Cardiovascular Care. J Am Coll Cardiol. 2018;71(10):1078–89.
doi: 10.1016/j.jacc.2017.12.064
pubmed: 29519347
pmcid: 5846485
Tran DT, Palfrey D, Welsh R. The Healthcare Cost Burden in adults with high risk for Cardiovascular Disease. Pharmacoecon Open. 2021;5(3):425–35.
doi: 10.1007/s41669-021-00257-8
pubmed: 33484443
pmcid: 8333236
ACSS. Operacionalização da Contratualização nos Cuidados de Saúde Primários para 2019. [cited 2024 Aug 14]. http://accsinternet-qua2.azurewebsites.net/wp-content/uploads/2019/02/20190214_Operacionalizacao_CSP_2019_vf.pdf
Portaria no 163/2013. Diário da República: I Série, n.
Portaria no 20/2014. Diário da República, 1.
Portaria no 234/2015. Diário da República, 1.
Portaria no 207/2017. Diário da República, 1.
Portaria no 254/2018. Diário da República, 1.
ACSS. Termos de Referência para contratualização de cuidados de saúde no SNS 2023. 2022.
Steen Carlsson K, Nilsson K, Wolden ML, Faurby M. Economic burden of atherosclerotic cardiovascular disease: a matched case-control study in more than 450,000 Swedish individuals. BMC Cardiovasc Disord. 2023;23(1):483.
doi: 10.1186/s12872-023-03518-y
pubmed: 37773098
pmcid: 10540350
Current health expenditure per capita (current US$.) - World. World Bank Open Data. [cited 2024 Jul 23]. https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD?locations=1W&skipRedirection=true&view=map
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.
doi: 10.1056/NEJMsb1609216
pubmed: 27959688